Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received a consensus rating of “Hold” from the twelve research firms that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $26.57.
A number of brokerages have commented on VNDA. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Friday, August 2nd. ValuEngine raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Citigroup raised shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Thursday, August 1st. Oppenheimer set a $18.00 target price on shares of Vanda Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, May 5th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $17.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, July 31st.
In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $15.34, for a total transaction of $1,117,856.48. Following the transaction, the chief executive officer now directly owns 1,276,343 shares of the company’s stock, valued at approximately $19,579,101.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.20% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its position in Vanda Pharmaceuticals by 5.2% during the 2nd quarter. BlackRock Inc. now owns 8,987,677 shares of the biopharmaceutical company’s stock worth $126,636,000 after purchasing an additional 447,529 shares during the last quarter. Renaissance Technologies LLC grew its position in Vanda Pharmaceuticals by 9.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,798,050 shares of the biopharmaceutical company’s stock worth $39,425,000 after purchasing an additional 233,300 shares during the last quarter. Invesco Ltd. grew its position in Vanda Pharmaceuticals by 1.6% during the 2nd quarter. Invesco Ltd. now owns 1,521,183 shares of the biopharmaceutical company’s stock worth $21,434,000 after purchasing an additional 24,525 shares during the last quarter. Stonepine Capital Management LLC grew its position in Vanda Pharmaceuticals by 6.5% during the 2nd quarter. Stonepine Capital Management LLC now owns 1,341,943 shares of the biopharmaceutical company’s stock worth $18,908,000 after purchasing an additional 81,655 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new position in Vanda Pharmaceuticals during the 2nd quarter worth $13,388,000. 99.33% of the stock is currently owned by institutional investors.
Vanda Pharmaceuticals stock traded up $0.08 during mid-day trading on Friday, reaching $14.88. 12,318 shares of the company’s stock were exchanged, compared to its average volume of 912,405. Vanda Pharmaceuticals has a twelve month low of $11.83 and a twelve month high of $33.44. The stock’s fifty day simple moving average is $13.87. The firm has a market capitalization of $801.24 million, a P/E ratio of 30.96 and a beta of 0.38.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The company had revenue of $59.06 million for the quarter, compared to the consensus estimate of $54.19 million. During the same period in the prior year, the firm posted $0.15 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts predict that Vanda Pharmaceuticals will post 0.32 earnings per share for the current year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Read More: Depreciation
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.